A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...

Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.

MangoRx said it “strongly refutes” claims made by Eli Lilly that it improperly copied blockbuster weight-loss medicines for ...

WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing more benefits of these powerful medicines, it’s no wonder appetite ...

President Biden and Sen. Bernie Sanders (I-Vt.) will travel to New Hampshire on Tuesday to speak on health care savings ...

For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...

Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular ...

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.

Novo Nordisk NVO shares have lost 4.5% in the past month compared with the industry’s decline of 1.5%. The company has also ...

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...

Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...